[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志,2010,18(3):163-166.
[2] Bellentani S.The epidemiology of non-alcoholic fatty li-ver disease[J]. Liver Int,2017,37(Suppl 1):81-84.
[3] Fan JG, Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol,2009,50(1):204-210.
[4] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[5] Rinella ME.Nonalcoholic fatty liver disease: a systematic review[J]. JAMA,2015,313(22):2263-2273.
[6] Powell EE, Cooksley WG, Hanson R, et al.The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years[J]. Hepatology,1990,11(1):74-80.
[7] Marengo A, Rosso C, Bugianesi E.Liver cancer: Connections with obesity, fatty liver, and cirrhosis[J]. Ann Rev Med,2016,67:103-117.
[8] Ertle J, Dechene A, Sowa JP, et al.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis[J]. Int J Cancer,2010, 128(10):2436-2443.
[9] Dyson J, Jaques B, Chattopadyhay D, et al.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team[J]. J Hepatol,2014,60(1):110-117.
[10] Younossi ZM, Otgonsuren M, Henry L, et al.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology,2015,62(6):1723-1730.
[11] Salomao MS, Yu WM, Brown RS, et al.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH[J]. Am J Surg Pathol,2010,34(11):1630-1636.
[12] Salomao MS, Remotti H, Vaughan R, et al.The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis[J]. Hum Pathol,2012,43(5):737-746.
[13] Shibahara J, Ando S, Sakamoto Y, et al.Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients[J]. Histopathology,2014,64(7):951-962.
[14] Calwell SH, Lee VD, Kleiner DE, et al.NASH and cryptogenic cirrhosis: a histological analysis[J]. Ann Hepatol,2009,8(4):346-352.
[15] Mittal S, Sada Y, El-Serag HB, et al.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population[J]. Clin Gastroenterol Hepatol,2015,13(3):594-601.
[16] Kikuchi L, Oliveira CP, Alvares-da-Silva MR, et al. Hepa-tocellular carcinoma management in nonalcoholic fatty liver disease patients: applicability of the BCLC staging system[J]. Am J Clin Oncol,2016,39(5):428-432.
[17] Wong RJ, Aguilar M, Cheung R, et al.Nonalcoholic steatohepatitis is the second leading etiology of liver di-sease among adults awaiting liver transplantation in the United States[J]. Gastroenterology,2015,148(3):547-555.
[18] Vigano L, Conci C, Cescon M, et al.Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC[J]. J Hepatol,2015,63(1):93-101.
[19] Reddy SK, Steel JL, Chen HW, et al.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver di-sease[J]. Hepatology,2012,55(6):1809-1819.
[20] Piscaglia F, Svegliati-Baroni G, Barchetti A, et al.Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study[J].Hepatology,2016,63(3):827-838.
[21] White DL, Kanwal F, El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review[J]. Clin Gastroenterol Hepatol,2012,10(12):1342-1359.
[22] Bruix J, Sherman M.Management of hepatocellular carcinoma: an update[J]. Hepatology,2011,53(3):1020-1022.
[23] Singal AG, Yopp AC, Gupta S, et al.Failure rates in the hepatocellular carcinoma surveillance process[J]. Cancer Prev Res,2012,5(9):1124-1130.
[24] Gopal P, Yopp AC, Waljee AK, et al.Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis[J]. Clin Gastroenterol Hepatol,2014,12(5):870-877.
[25] Kawanaka M, Tomiyama Y, Hyogo H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease[J]. Hepatol Res,2018-01-07[Epub ahead of print]
[26] Zhang H, Gao C, Fang L, et al.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis[J]. Scand J Gastroenterol,2013,48(1):78-87.
[27] Bhat M, Sonenberg N, Gores GJ.The mTOR pathway in hepatic malignancies[J]. Hepatology,2013,58(2):810-818.
[28] Singh S, Singh PP, Singh AG, et al.Statins are associa-ted with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis[J]. Gastroenterology,2013,144(2):323-332.
[29] Yang B, Yang HP, Ward KK, et al.Bariatric surgery and liver cancer in consortium of academic medical centers[J]. Obes Surg,2016,26(3):696-700.
[30] Torres DM, Williams CD, Harrison SA.Features, diagnosis, and treatment of nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2012,10(8):837-858.
[31] Wen CP, Lin J, Yang CY, et al.Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases[J]. J Natl Cancer Inst,2012,104(20):1599-1611.
[32] Piguet AC, Saran U, Simillion C, et al.Regular exercise decreases liver tumors development in hepatocyte-speci-fic PTEN-deficient mice independently of steatosis[J]. J Hepatol,2015,62(6):1296-1303.
